4.32
Goodrx Holdings Inc stock is traded at $4.32, with a volume of 1.84M.
It is up +1.89% in the last 24 hours and down -7.89% over the past month.
GoodRx Holdings Inc is a consumer-focused digital healthcare platform that aims to lower the cost of healthcare in the United States. It operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and provides access to negotiated prices through codes that can be used to save money on prescriptions across the United States. GoodRx generates revenue from core business from pharmacy benefit managers (PBMs) that manage formularies and prescription transactions including establishing pricing between consumers and pharmacies. It also offers various healthcare products and services, including pharma manufacturer solutions, subscriptions, and telehealth services.
See More
Previous Close:
$4.24
Open:
$4.21
24h Volume:
1.84M
Relative Volume:
1.18
Market Cap:
$1.68B
Revenue:
$775.09M
Net Income/Loss:
$-58.68M
P/E Ratio:
-32.58
EPS:
-0.1326
Net Cash Flow:
$64.06M
1W Performance:
-7.69%
1M Performance:
-7.89%
6M Performance:
-11.66%
1Y Performance:
-37.66%
Goodrx Holdings Inc Stock (GDRX) Company Profile
Name
Goodrx Holdings Inc
Sector
Industry
Phone
(855) 268-2822
Address
2701 OLYMPIC BOULEVARD, SANTA MONICA
Compare GDRX with other stocks
Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
---|---|---|---|---|---|---|
![]()
GDRX
Goodrx Holdings Inc
|
4.32 | 1.68B | 775.09M | -58.68M | 64.06M | -0.1326 |
![]()
VEEV
Veeva Systems Inc
|
237.05 | 38.54B | 2.75B | 714.14M | 1.09B | 4.33 |
![]()
DOCS
Doximity Inc
|
59.19 | 11.13B | 516.85M | 174.11M | 217.38M | 0.87 |
![]()
TEM
Tempus Ai Inc
|
61.37 | 9.87B | 640.44M | -743.28M | -206.93M | -11.29 |
![]()
HQY
Healthequity Inc
|
90.40 | 7.83B | 1.15B | 96.70M | -161.99M | 1.09 |
![]()
WAY
Waystar Holding Corp
|
40.01 | 7.04B | 906.14M | -52.62M | 89.62M | -0.3621 |
Goodrx Holdings Inc Stock (GDRX) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Dec-04-24 | Initiated | Mizuho | Neutral |
Aug-09-24 | Upgrade | Raymond James | Outperform → Strong Buy |
May-23-24 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
May-16-24 | Upgrade | Raymond James | Mkt Perform → Outperform |
Apr-10-24 | Upgrade | KeyBanc Capital Markets | Sector Weight → Overweight |
Mar-25-24 | Upgrade | Wells Fargo | Equal Weight → Overweight |
Mar-01-24 | Upgrade | JP Morgan | Neutral → Overweight |
Feb-26-24 | Initiated | Leerink Partners | Outperform |
Jan-02-24 | Downgrade | BofA Securities | Buy → Underperform |
Aug-10-23 | Upgrade | DA Davidson | Neutral → Buy |
Jul-31-23 | Upgrade | TD Cowen | Market Perform → Outperform |
Dec-01-22 | Initiated | Citigroup | Buy |
Nov-04-22 | Upgrade | JP Morgan | Underweight → Neutral |
Sep-16-22 | Initiated | KeyBanc Capital Markets | Sector Weight |
Sep-07-22 | Initiated | Truist | Hold |
Aug-12-22 | Initiated | DA Davidson | Neutral |
Jun-10-22 | Downgrade | Goldman | Buy → Neutral |
Jun-06-22 | Resumed | BofA Securities | Buy |
Jun-01-22 | Downgrade | Robert W. Baird | Outperform → Neutral |
May-10-22 | Downgrade | Evercore ISI | Outperform → In-line |
May-10-22 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
May-10-22 | Downgrade | Raymond James | Outperform → Mkt Perform |
May-10-22 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
Apr-11-22 | Initiated | Wells Fargo | Equal Weight |
Apr-07-22 | Initiated | Guggenheim | Buy |
Apr-01-22 | Resumed | Credit Suisse | Neutral |
Mar-15-22 | Upgrade | Robert W. Baird | Neutral → Outperform |
Mar-01-22 | Reiterated | Barclays | Overweight |
Mar-01-22 | Reiterated | BofA Securities | Neutral |
Mar-01-22 | Downgrade | Cowen | Outperform → Market Perform |
Mar-01-22 | Downgrade | Credit Suisse | Outperform → Neutral |
Mar-01-22 | Reiterated | Evercore ISI | Outperform |
Mar-01-22 | Reiterated | Goldman | Buy |
Mar-01-22 | Reiterated | JP Morgan | Underweight |
Mar-01-22 | Reiterated | RBC Capital Mkts | Outperform |
Mar-01-22 | Reiterated | SVB Leerink | Outperform |
Jan-07-22 | Initiated | Goldman | Buy |
Dec-21-21 | Initiated | Stephens | Overweight |
Dec-02-21 | Initiated | Jefferies | Buy |
Aug-31-21 | Upgrade | Barclays | Equal Weight → Overweight |
Aug-13-21 | Upgrade | Raymond James | Mkt Perform → Outperform |
May-28-21 | Initiated | Robert W. Baird | Neutral |
Apr-06-21 | Resumed | Evercore ISI | Outperform |
Jan-25-21 | Initiated | Guggenheim | Buy |
Nov-19-20 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
Nov-18-20 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
Oct-19-20 | Initiated | Barclays | Equal Weight |
Oct-19-20 | Initiated | BofA Securities | Neutral |
Oct-19-20 | Initiated | Citigroup | Buy |
Oct-19-20 | Initiated | Cowen | Outperform |
Oct-19-20 | Initiated | Credit Suisse | Outperform |
Oct-19-20 | Initiated | Deutsche Bank | Hold |
Oct-19-20 | Initiated | Goldman | Neutral |
Oct-19-20 | Initiated | JP Morgan | Neutral |
Oct-19-20 | Initiated | Morgan Stanley | Overweight |
Oct-19-20 | Initiated | RBC Capital Mkts | Sector Perform |
Oct-19-20 | Initiated | SVB Leerink | Outperform |
Oct-19-20 | Initiated | UBS | Buy |
View All
Goodrx Holdings Inc Stock (GDRX) Latest News
GoodRx Holdings First Quarter 2025 Earnings: EPS Misses Expectations - Yahoo Finance
GoodRx Holdings, Inc. (NASDAQ:GDRX) Q1 2025 Earnings Call Transcript - Insider Monkey
GoodRx Holdings (GDRX) Price Target Lowered by Goldman Sachs | GDRX Stock News - GuruFocus
GoodRx Holdings Inc (GDRX) Q1 2025 Earnings Call Highlights: Revenue Growth and Strategic Initiatives Amid Challenges - GuruFocus
GoodRx Reports Strong Q1 2025 Results - TipRanks
Decoding GoodRx Holdings Inc (GDRX): A Strategic SWOT Insight - GuruFocus
Earnings call transcript: GoodRx stock surges after Q1 2025 earnings By Investing.com - Investing.com Nigeria
BofA cuts GoodRx stock price target to $4 on MAC concerns By Investing.com - Investing.com South Africa
GoodRx Earnings Call: Mixed Sentiment with Growth and Challenges - TipRanks
GoodRx Holdings, Inc. (GDRX) Q1 Earnings Match Estimates - MSN
GoodRx (GDRX) Stock Surges on Quarterly Earnings and Guidance Up - GuruFocus
Why GoodRx Holdings Stock Triumphed on Thursday - Yahoo Finance
KeyBanc maintains GoodRx stock Overweight with $6 target By Investing.com - Investing.com India
BofA cuts GoodRx stock price target to $4 on MAC concerns - Investing.com Australia
Goodrx outlines 2025 revenue guidance of $810M-$840M with focus on pharmacy partnerships - MSN
Medicare Changes on the Way? - marketscreener.com
Transcript : GoodRx Holdings, Inc., Q1 2025 Earnings Call, May 08, 2025 - marketscreener.com
GDRX vs. PGNY: Which Stock Should Value Investors Buy Now? - Yahoo Finance
Is GoodRx (GDRX) a Great Value Stock Right Now? - Yahoo Finance
Earnings call transcript: GoodRx stock surges after Q1 2025 earnings - Investing.com
Compared to Estimates, GoodRx (GDRX) Q1 Earnings: A Look at Key Metrics - MSN
Leerink maintains GoodRx stock Outperform with $9 target - Investing.com Australia
Leerink maintains GoodRx stock Outperform with $9 target By Investing.com - Investing.com Nigeria
BofA Adjusts Price Target for GoodRx (GDRX) Amid Mixed Earnings Report | GDRX Stock News - GuruFocus
KeyBanc maintains GoodRx stock Overweight with $6 target - Investing.com
KeyBanc Reiterates Overweight Rating on GoodRx Holdings Inc. (GDRX) - StreetInsider
GoodRx Holdings Inc. (GDRX) PT Lowered to $4 at BofA Securities - StreetInsider
GoodRx Reports First Quarter 2025 Results - 01net
GoodRx Holdings Inc reports results for the quarter ended March 31Earnings Summary - TradingView
GoodRx’s (NASDAQ:GDRX) Q1 Earnings Results: Revenue In Line With Expectations, Stock Jumps 10.3% - Yahoo Finance
GoodRx Holdings Swings To Q1 Profit - Nasdaq
GoodRx Holdings Inc Reports Q1 2025 Earnings: EPS of $0.03 Misses Estimate, Revenue of $203 Million Slightly Beats Estimate - GuruFocus
GoodRx Holdings, Inc. SEC 10-Q Report - TradingView
GoodRx Holdings, Inc. (GDRX) Reports In-Line Q1 EPS, Beats on Revenue; Offers FY25 Revenue Guidance - StreetInsider
GoodRx Holdings Inc (GDRX) Q1 2025: Everything You Need To Know Ahead Of Earnings - GuruFocus
Press Release Distribution & PR Platform - ACCESS Newswire
GoodRx Holdings, Inc. (GDRX) Reports Next Week: Wall Street Expects Earnings Growth - Yahoo Finance
GoodRx Holdings, Inc.'s (NASDAQ:GDRX) Stock Has Shown A Decent Performance: Have Financials A Role To Play? - Yahoo Finance
LPL Financial LLC Increases Holdings in GoodRx Holdings, Inc. (NASDAQ:GDRX) - Defense World
Wells Fargo Adjusts Price Target for GoodRx (GDRX), Cites Compet - GuruFocus
GoodRx Holdings, Inc. (NASDAQ:GDRX) Receives Consensus Rating of “Moderate Buy” from Analysts - Defense World
Shareholders that Lost Money on GoodRx Holdings, Inc.(GDRX) Urged to Join Class ActionContact Levi & Korsinsky to Learn More - ACCESS Newswire
Attorney General Fitch secures restraining order against GoodRx and affiliates over pharmacy reimbursements - Picayune Item
Private equity firms who hold 55% of GoodRx Holdings, Inc. (NASDAQ:GDRX) gained 3.6%, institutions profited as well - simplywall.st
GoodRx Beats Investor Suit Over Kroger-Linked Biz - Law360
3 Reasons to Sell GDRX and 1 Stock to Buy Instead - The Globe and Mail
Why GoodRx Holdings (GDRX) Is Among the Best Telehealth Stocks to Buy Now - Insider Monkey
TD Cowen Sticks to Their Buy Rating for GoodRx Holdings (GDRX) - The Globe and Mail
Goodrx Holdings Inc Stock (GDRX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):